Genmab revenue increased 21% compared to the first nine months of 2024, to $2,662 million FDA granted BTD to Rina-S ® in advanced endometrial cancer Epcoritamab Phase 3 EPCORE ® FL-1 trial met dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback